Huiyu Pharmaceutical(SH:688553)2026-01-29 07:50Revenue Projections - The company expects 2025 annual revenue to be between 960 million and 1.09 billion yuan, representing a year-on-year decline of 12.28% to 0.40%[4]. - The projected net loss attributable to shareholders for 2025 is estimated to be between 29 million and 24 million yuan, a year-on-year decline of 108.91% to 107.38%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 78 million and 93 million yuan, showing a year-on-year decline of 15.33% to a growth of 0.96%[4]. Previous Year Performance - The previous year's net profit attributable to shareholders was 325.39 million yuan, with a total profit of 349.70 million yuan[7]. - The company reported earnings per share of 0.77 yuan for the previous year[8]. Performance Change Factors - The main reason for the performance change is the fair value loss of 173 million yuan due to the stock price fluctuation of the invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd.[9]. Financial Data and Audit - The financial data in the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the finance department[5]. - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast as of the announcement date[10]. - The final and accurate financial data will be disclosed in the audited annual report for 2025[11]. Investment Risks - Investors are advised to pay attention to investment risks due to the potential significant impact of stock price fluctuations on the company's financial statements[11].